Newspaper logo  
 
 
Local Gov’t Stories, Events

08.15 RIDE FOR THE OVERRIDE

Ref. : Civic Events

Ref. : Arts & Education Events

Ref. : Public Service Notices

01.15 Stoop stories

Travel
Books, Films, Arts & Education
Letters

Ref. : Letters to the editor

Health Care & Environment

01.16 At Scott Pruitt’s Confirmation Hearing, Science Will Be on Trial

01.15 Bernie Sanders Shreds Fellow Democrats Who Voted with Big Pharma

01.14 Dow Chemical Wants Farmers to Keep Using a Pesticide Linked to Autism and ADHD [serious]

01.14 ‘The last five years have not been great at Greenpeace’

01.14 Patagonia, Black Diamond take on Utah officials over public land rights [if there is a way to screw the public, Republicans are working on it...]

01.14 All north Indian cities fail to meet air quality standards, report finds

News Media Matters

Daily: FAIR Blog
The Daily Howler

US Politics, Policy & 'Culture'

01.16 Trump, and the world, readies for a ‘leap into the dark’

01.16 Democrats sweat Clinton vs. Sanders rift

01.16 JOHN LEWIS, DONALD TRUMP, AND THE MEANING OF LEGITIMACY

01.16 Trump’s Team Is Shaping Up to Be Dangerously Incoherent

01.15 How Betsy DeVos Used God and Amway to Take Over Michigan Politics

01.15 Fear and loathing in Washington DC: progressives dread Trump inauguration

01.14 California Mobilizes for War Against Trump

01.14 A Firestorm of Protests Will Take Aim at Donald Trump's Inauguration

01.14 Transition Team Assures Public Trump Has Too Many Conflicts Of Interest To Favor Any Specific One [humorous(?) truth]

01.14 GOP House Takes Next Step Toward Taking Healthcare Away From Millions

01.14 Obamacare Repeal = $7 Million Tax Cut for Nation's Richest 400 People [The sick get sicker so the rich get richer!]

Justice Matters
High Crimes?
Economics, Crony Capitalism

01.16 The Trump Deficit

01.16 World's eight richest people have same wealth as poorest 50%

01.12 Nation's First "For-Profit President" as Trump Refuses To Divest

01.11 The Age of Trump

01.10 Jeremy Corbyn calls for maximum wage law

International

01.16 Lessons from Germany for Integrating Refugees

01.16 The world needs a new strategy to tackle the migration crisis

01.15 The Pope Says Yes to Palestine: Embassy Opens in Vatican

01.15 Hammond threatens EU with aggressive tax changes after Brexit

01.15 Get tougher on tax avoidance or we will block deal, say Dutch [fantastic!]

01.15 Silk Road route back in business as China train rolls into London

01.15 Women's March on Washington set to be one of America's biggest protests

01.14 Emergence of populist leaders threatens democracy, says Human Rights Watch

01.14 Iran repopulates Syria with Shia Muslims to help tighten regime's control

01.14 Watch out, Europe. Germany is top of Russian hackers’ list [Russia's hacks help twist and/or legitimize fake[?] news stories to its benefit, as Putin 'plays' them like chess gambits]

We are a non-profit Internet-only newspaper publication founded in 1973. Your donation is essential to our survival.

You can also mail a check to:
Baltimore News Network, Inc.
P.O. Box 42581
Baltimore, MD 21284-2581
Google
This site Web
  Big Pharma Wins Big in Health Care Reform

COMMENTARY:

Big Pharma Wins Big in Health Care Reform

by James Ridgeway
First published in his blog Unsilent Generation yesterday, 22 March 2010
To a large extent, the “debate” over health care was a show debate, an extended round of Washington smoke and mirrors. The administration early on cut its deal with Big Pharma, and pretty much stuck to it throughout the process.

The Republicans look a sour lot this morning, but the pharmaceutical industry, which helps foot the campaign bills of a sizeable chunk of members of both parties, is delighted with the legislation, and with its Democratic friends in the White House and on the Hill.

Members of Congress in both parties generally have lined up behind the insurance and pharmaceutical industries from the get go. So it should come as no surprise that the Democrats, who long ago gave up any pretence of opposing corporate power, found a way to accomodate the pharmaceutical companies on the way to its tepid reform. To a large extent, the “debate” over health care was a show debate, an extended round of Washington smoke and mirrors. The administration early on cut its deal with Big Pharma, and pretty much stuck to it throughout the process.

In fact, the Dems actually made the drugsters look good, celebrating the industry’s generous “concessions” and “discounts” while ensuring that no real threat to Big Pharma’s profits would make their way into the final bill.

The industry’s main goal from the very beginning has been to fend off any government power to negotiate or seriously regulate drug prices–and this they did.

Big Pharma’s second big win was to prevent any measure that would have opened the way for American consumers to buy less expensive drugs abroad, especially from Canada.

At the same time, the supposed give-backs by the drug industry are projected to more than pay for themselves. The much-lauded discounts on brand name drugs for seniors in the Medicare prescription drug program, for example, are good for Big Pharma because they discourage oldsters from switching to generics.

And more insured people simply mean more money coming into the coffers, for Big Pharma as well as for the insurance industry.

Confirmation of the industry analysis came early in the day from the stock market, where drug stocks initially remained level; there certainly was no rush to dump shares, which is what would be expected if the bill actually represented any threat to profits. And by 1 p, EST, CNN Money was reporting a rally in health care stocks.

“I was unable to find anything in there that would cause me to have anxiety if I were a shareholder in a pharmaceutical company,” Ira Loss, a senior health-care analyst at the research firm Washington Analysis, told Dow Jones. According to the ticker story:

Billy Tauzin, who led the industry’s negotiations on health care with lawmakers, said overall drug makers fare well. “While we’re not totally happy,” Tauzin began, “we generally feel like it tracks with our principles.”

Sanofi-Aventis SA (SNY) Chief Executive Christopher Viehbacher said in an interview that the impact of the legislation will be neutral to slightly negative “but better for the industry than if healthcare reform didn’t pass.”

Tauzin, head of the Pharmaceutical Research and Manufacturers of America or PhRMA, and Viehbacher said getting protection for brand-name biologics is among the important provisions for the industry. Drug makers pushed hard to get 12 years of exclusive market protection while the White House and some lawmakers wanted to lower the protection to seven years.

Despite fees and rebates imposed by the legislation, “analysts say drug makers will end up recouping those costs through new customers: The bill would provide insurance coverage to an additional 32 million Americans.” The Dow Jones story continues:

Chalk up another good round for Pharma and Biotech in health care reform,” began a note to clients Friday from Concept Capital, a research firm.Ken Tsuboi, co-manager of the Allianz RCM Wellness Fund, sees the impact of bill, and its $90 billion in concessions over 10 years, as relatively minor in an industry that has annual global sales of about $750 billion, with about $300 billion in the U.S., and margins close to 30%.”I think that it is actually a pretty good deal for Pharma,” Tsuboi said.

The GOP, which purports to be the party of big business, ought to be applauding at least these portions of the health care reform—and perhaps when the cameras go away, some of them will quit bitching and count their blessings. As for the obnoxious Tea Party gang, if they start threatening the real power in this country, which is vested in corporations, they may well find themselves whipped and isolated.


Born in 1936, James Ridgeway has been reporting on politics for more than 45 years. He is currently Senior Washington Correspondent for Mother Jones, and recently wrote a blog on the 2008 presidential election for the Guardian online. He previously served as Washington Correspondent for the Village Voice; wrote for Ramparts and The New Republic; and founded and edited two independent newsletters, Hard Times and The Elements.

Ridgeway is the author of 16 books, including The Five Unanswered Questions About 9/11, It’s All for Sale: The Control of Global Resources, and Blood in the Face: The Ku Klux Klan, Aryan Nations, Nazi Skinheads, and the Rise of a New White Culture. He co-directed a companion film to Blood in the Face and a second documentary film, Feed, and has co-produced web videos for GuardianFilms.

Additional information and samples of James Ridgeway’s work can be found at JamesRidgeway.net and at his newest web site, Solitary Watch.

This article is republished in the Baltimore Chronicle with permission of the author.



Copyright © 2010 The Baltimore News Network. All rights reserved.

Republication or redistribution of Baltimore Chronicle content is expressly prohibited without their prior written consent.

Baltimore News Network, Inc., sponsor of this web site, is a nonprofit organization and does not make political endorsements. The opinions expressed in stories posted on this web site are the authors' own.

This story was published on March 23, 2010.
 



Public Service Ads:
Verifiable Voting in Maryland